VRM
NVO

Vectors Research Management’s Novo Nordisk NVO Stock Holding History

Vectors Research Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-600
Closed -$33K – 363
2022
Q2 		$33K Hold
600
– – 0.01% 253
2022
Q1 		$33K Hold
600
– – 0.01% 253
2021
Q4 		$34K Hold
600
– – 0.01% 288
2021
Q3 		$29K Hold
600
– – 0.01% 278
2021
Q2 		$25K Hold
600
– – 0.01% 297
2021
Q1 		$20K Hold
600
– – 0.01% 284
2020
Q4 		$21K Hold
600
– – 0.01% 264
2020
Q3 		$21K Hold
600
– – 0.01% 240
2020
Q2 		$20K Buy
+600
New +$19.1K 0.01% 239

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Vectors Research Management's NVO Position: Q3 2022 in Review

Vectors Research Management sold out of Novo Nordisk (NVO) in Q3 2022, closing a stake of 600 shares — an estimated $33K sold.

Vectors Research Management first reported a position in NVO in Q2 2020 and held it in 9 quarters. The position peaked at $34K in Q4 2021. 907 funds tracked by Wall St. Rank hold NVO as of Q3 2022.

  • Vectors Research Management reported no remaining Novo Nordisk position as of Q3 2022 after selling out during the quarter.
  • Vectors Research Management sold 600 Novo Nordisk shares in Q3 2022, an estimated $33K.
  • Vectors Research Management first reported a position in Novo Nordisk in Q2 2020 and held it in 9 quarters.
  • Vectors Research Management's Novo Nordisk position peaked at $34K in Q4 2021.
  • 907 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.